Abstract

Stem cells have been the focus of intense research opening up new possibilities for the treatment of various diseases. Mesenchymal stromal cells (MSCs) are multipotent cells with relevant immunomodulatory properties and are thus considered as a promising new strategy for immune disease management. To enhance their efficiency, several issues related to both MSC biology and functions are needed to be identified and, most importantly, well clarified. The sources from which MSCs are isolated are diverse and might affect their properties. Both clinicians and scientists need to handle a phenotypic-characterized population of MSCs, particularly regarding their immunological profile. Moreover, it is now recognized that the tissue-reparative effects of MSCs are based on their immunomodulatory functions that are activated following a priming/licensing step. Thus, finding the best ways to pre-conditionate MSCs before their injection will strengthen their activity potential. Finally, soluble elements derived from MSC-secretome, including extracellular vesicles (EVs), have been proposed as a cell-free alternative tool for therapeutic medicine. Collectively, these features have to be considered and developed to ensure the efficiency and safety of MSC-based therapy. By participating to this Special Issue “Mesenchymal Stem/Stromal Cells in Immunity and Disease”, your valuable contribution will certainly enrich the content and discussion related to the thematic of MSCs.

Highlights

  • In order to achieve uniform characterization of Mesenchymal stromal cells (MSCs) and facilitate the comparison of data among investigators, the International Society for Cellular Therapy (ISCT) as well as the International Federation for Adipose Therapeutics and Science (IFATS) have established a minimal set of standard criteria to define human MSCs according to their tissue origins [18,19]

  • Recent data highlighted that MSCs, depending on their tissue-source, present several relevant receptors, including advanced glycation end-products (RAGE) receptor; C-type lectin receptors (CLRs, including DECTIN-1, DECTIN-2, and MINCLE); leukotriene B4 (LTB4) receptors (BLT1 and BLT2); and cysteinyl leukotrienes (CysLTs) receptors (CYSLTR1 and CYSLTR2), which are potentially involved in the regulation of inflammatory and immunological responses [26]

  • Recent studies have revealed that implanted cells do not survive for long and that the benefits of MSC therapy could be attributed to their paracrine activity

Read more

Summary

Introduction

Cell-based therapy is being increasingly considered an efficacious and safe option for different therapeutic applications. The use of stem cells in new medicinal therapies includes treatment of different conditions [1].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call